Filing Flows › Charles River Laboratories International (CRL) › How it makes money
How Charles River Laboratories International (CRL) makes money
Charles River Laboratories International (CRL) made $983M of revenue in the third quarter 2026 (Q3 2026), -2% from a year earlier. DSA brought in $596M (61%); RMS brought in $208M (21%); Manufacturing brought in $179M (18%). Of every dollar of revenue, 21¢ was left as operating profit, 34¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| DSA | $596M | 60.7% | -2% | -0.7% |
| RMS | $208M | 21.1% | -0.9% | -3% |
| Manufacturing | $179M | 18.2% | -5% | -6% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $983M | 100.0% |
| Operating profit | $203M | 20.6% |
| Net earnings | $333M | 33.9% |
| Operating cash flow | $254M | 25.9% |
| Free cash flow | $207M | 21.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $983M | -2% |
| Q2 2026 | $1.0B | -3% |
| Q1 2026 | $996M | +1% |
| Q4 2025 | $994M | -0.8% |
| Q3 2025 | $1.0B | -0.5% |
| Q2 2025 | $1.0B | +0.6% |
| Q1 2025 | $984M | -3% |
From Charles River Laboratories International's 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Charles River Laboratories International make money?
Charles River Laboratories International (CRL) made $983M of revenue in the third quarter 2026 (Q3 2026), -2% from a year earlier. DSA brought in $596M (61%); RMS brought in $208M (21%); Manufacturing brought in $179M (18%). Of every dollar of revenue, 21¢ was left as operating profit, 34¢ was left as net earnings.
What is Charles River Laboratories International's biggest business?
DSA: $596M in the third quarter 2026, 61% of revenue, -0.7% from a year earlier.
What is Charles River Laboratories International's profit margin?
Net earnings were $333M, 33.9% of revenue, in the third quarter 2026; the operating margin was 20.6%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.